Among the various small molecule inhibitors that specifically target the tyrosine kinase activity of EGFR (i.e., EGFR-tyrosine kinase inhibitors (EGFR-TKIs)), gefitinib and erlotinib are the most commonly used molecular-targeted therapeutics for NSCLC patients1. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.